CD79A and neoplasm: To study the overcoming of resistance to therapeutic IgA therapy in cancer cells through CD47 blockade, we investigated the combination of IgA antibodies and disruption of the CD47/SIRPα axis, a well-studied myeloid checkpoint pathway, in the context of tumor cell killing by neutrophils.